J
Jean-Yves Blay
Researcher at Claude Bernard University Lyon 1
Publications - 927
Citations - 55977
Jean-Yves Blay is an academic researcher from Claude Bernard University Lyon 1. The author has contributed to research in topics: Sarcoma & Medicine. The author has an hindex of 104, co-authored 808 publications receiving 45637 citations. Previous affiliations of Jean-Yves Blay include Institut Gustave Roussy & European Organisation for Research and Treatment of Cancer.
Papers
More filters
Journal ArticleDOI
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
Winette T. A. van der Graaf,Jean-Yves Blay,Sant P. Chawla,Dong Wan Kim,B. Bui-Nguyen,Paolo G. Casali,Patrick Schöffski,Massimo Aglietta,Arthur P. Staddon,Yasuo Beppu,Axel Le Cesne,Hans Gelderblom,Ian Judson,Nobuhito Araki,M. Ouali,Sandrine Marreaud,Rachel Hodge,Mohammed R. Dewji,Corneel Coens,George D. Demetri,Christopher D.M. Fletcher,Angelo Paolo Dei Tos,Peter Hohenberger +22 more
TL;DR: This phase 3 study investigated the effect of pazopanib on progression-free survival in patients with metastatic non-adipocytic soft-tissue sarcoma after failure of standard chemotherapy.
Journal ArticleDOI
Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial*
Jaap Verweij,Paolo G. Casali,John Zalcberg,A. Lecesne,Peter Reichardt,Jean-Yves Blay,Rolf D. Issels,Allan T. van Oosterom,Pancras C.W. Hogendoorn,Martine Van Glabbeke,Rossella Bertulli,Ian Judson +11 more
TL;DR: If response induction is the only aim of treatment, a daily dose of400 mg of imatinib is sufficient; however, a dose of 400 mg twice a day achieves significantly longer progression-free survival.
Journal ArticleDOI
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
David M. Hyman,Igor Puzanov,Vivek Subbiah,Jason E. Faris,Ian Chau,Jean-Yves Blay,Juergen Wolf,Noopur Raje,Eli L. Diamond,Antoine Hollebecque,Radj Gervais,Maria Elena Elez-Fernandez,Antoine Italiano,Ralf-Dieter Hofheinz,Manuel Hidalgo,Emily Chan,Martin Schuler,Susan Frances Lasserre,Martina Makrutzki,Florin Sirzen,Maria Luisa Veronese,Josep Tabernero,José Baselga +22 more
TL;DR: BRAF V600 appears to be a targetable oncogene in some, but not all, nonmelanoma cancers and preliminary vemurafenib activity was observed in non-small-cell lung cancer and in Erdheim-Chester disease and Langerhans'-cell histiocytosis.
Journal ArticleDOI
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up†
Paolo G. Casali,N. Abecassis,Sebastian Bauer,R. Biagini,Stefan S. Bielack,Sylvie Bonvalot,Ioannis Boukovinas,Judith V.M.G. Bovée,Thomas Brodowicz,Javier Martin Broto,Angela Buonadonna,E. de Álava,A. P. Dei Tos,X.G. del Muro,Palma Dileo,Mikael Eriksson,Alexander Fedenko,Virginia Ferraresi,Andrea Ferrari,Silvia Ferrari,A.M. Frezza,Silvia Gasperoni,Hans Gelderblom,Thierry Gil,Giovanni Grignani,Alessandro Gronchi,Rick L. Haas,A. Hannu,B. Hassan,Peter Hohenberger,Rolf D. Issels,Heikki Joensuu,Robin L. Jones,Ian Judson,Paul C Jutte,Suzanne E. J. Kaal,Bernd Kasper,Katerina Kopeckova,D.A. Krakorova,A. Le Cesne,Iwona Lugowska,Ofer Merimsky,Michael Montemurro,Maria Abbondanza Pantaleo,R. Piana,Piero Picci,S. Piperno-Neumann,Antonio López Pousa,Peter Reichardt,M.H. Robinson,Piotr Rutkowski,Akmal Safwat,Patrick Schöffski,Stefan Sleijfer,Silvia Stacchiotti,K. Sundby Hall,M. Unk,F. van Coevorden,W.T.A. van der Graaf,Jeremy Whelan,Eva Wardelmann,Olga Zaikova,Jean-Yves Blay +62 more
Journal ArticleDOI
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
George D. Demetri,Peter Reichardt,Yoon-Koo Kang,Jean-Yves Blay,Piotr Rutkowski,Hans Gelderblom,Peter Hohenberger,Michael F. Leahy,Margaret von Mehren,Heikki Joensuu,Giuseppe Badalamenti,Martin E. Blackstein,Axel Le Cesne,Patrick Schöffski,Robert G. Maki,Sebastian Bauer,Binh Bui Nguyen,Jianming Xu,Toshirou Nishida,John Chung,Christian Kappeler,Iris Kuss,D. Laurent,Paolo G. Casali +23 more
TL;DR: The results of this study show that oral regorafenib can provide a significant improvement in progression-free survival compared with placebo in patients with metastatic GIST after progression on standard treatments.